Meta-analysis of tumor necrosis factor alpha -308 polymorphism and knee osteoarthritis risk

BMC Musculoskeletal Disorders

Yaochi Wu¹  Suotang Kou¹ 

[1] Acupuncture Moxibustion and Tuina traumatology of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

关键词: Meta-analysis;    Osteoarthritis;    -308 polymorphism;    TNF-α;   

Others  :  1092097
DOI  :  10.1186/1471-2474-15-373

 received in 2014-04-20, accepted in 2014-09-24,  发布年份 2014

【 摘 要 】

Background

Several case–control studies have been conducted to clarify the association between the tumor necrosis factor alpha (TNF-α) -G308A polymorphism and risk of osteoarthritis (OA); however, the results are inconsistent. This meta-analysis was performed to clarify this issue using all the available evidence.

Methods

Eligible articles were retrieved by searching PubMed, Web of science and Google scholar. The strength of the association between the TNF-α -G308A polymorphism and risk of OA was assessed by odds ratios (ORs) with the corresponding 95% confidence interval (CI) for each study.

Results

Seven studies were included in the meta-analysis, which included 983 OA cases and 1355 controls. The pooled analysis based on all included studies showed a significantly increased OA risk in the recessive genetic model analysis (OR = 11.08, 95% CI = 4.75-25.86, p < 0.001) and in the A allele vs. G allele analysis (OR = 2.30, 95% CI = 1.08-4.90). However, there was no statistical difference in the dominant genetic model analysis (OR = 2.45, 95% CI = 0.95-6.27, p = 0.06). Furthermore, we found that OA patients had a higher frequency of the AA genotype (OR = 10.49, 95% CI = 4.47-24.61) and GA genotype (OR = 1.78, 95% CI = 1.03-3.08) compared with the control population.

Conclusion

Our results suggested that the TNF-α -G308A polymorphism were associated with an increased risk of OA.

【 授权许可】

   
2014 Kou and Wu; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Murray CJL, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge: Harvard School of Public Health, on behalf of the World Health Organization; Global Burden of Disease and Injury Series, 1996. Vol. 1
• [2]Prasanna SS, Korner-Bitensky N, Ahmed S: Why do people delay accessing health care for knee osteoarthritis? Exploring beliefs of health professionals and lay people. Physiother Can 2013, 65(1):56-63.
• [3]Berenbaum F, Eymard F, Houard X: Osteoarthritis, inflammation and obesity. Curr Opin Rheumatol 2013, 25(1):114-118.
• [4]Esposito E, Cuzzocrea S: TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 2009, 16(24):3152-3167.
• [5]Pelletier JP, Martel-Pelletier J, Abramson SB: Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001, 44(6):1237-1247.
• [6]Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H: Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011, 7(1):33-42.
• [7]Stannus O, Jones G, Cicuttini F, Parameswaran V, Quinn S, Burgess J, Ding C: Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 2010, 18(11):1441-1447.
• [8]Xue J, Wang J, Liu Q, Luo A: Tumor necrosis factor-α induces ADAMTS-4 expression in human osteoarthritis chondrocytes. Mol Med Rep 2013, 8(6):1755-1760.
• [9]Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997, 94(7):3195-3199.
• [10]Messer G, Spengler U, Jung MC, Honold G, Blömer K, Pape GR, Riethmüller G, Weiss EH: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991, 173(1):209-219.
• [11]Aller R, de Luis DA, Izaola O, González Sagrado M, Conde R, Alvarez Gago T, Pacheco D, González JM, Velasco MC: G308A polymorphism of TNF-alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients. Ann Hepatol 2010, 9(4):439-444.
• [12]Zhang TC, Zhao YQ, Hu GL, Liu XQ, Huang XK: The relationship between tumour necrosis factor-α gene polymorphism and susceptibility and clearance of the persistent hepatitis B virus infection in a Chinese population: a meta-analysis. Clin Microbiol Infect 2013. doi:10.1111/1469-0691.12257
• [13]Ahmed HH, Taha FM, Darweesh HE, Morsi HM: Association between TNF promoter -308 G>A and LTA 252 A>G polymorphisms and systemic lupus erythematosus. Mol Biol Rep 2014, 41(4):2029-2036.
• [14]Tong Q, Zhao L, Qian XD, Zhang LL, Xu X, Dai SM, Cai Q, Zhao DB: Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics 2013, 14(14):1691-1700.
• [15]Sandhya P, Danda S, Danda D, Lonarkar S, Luke SS, Sinha S, Joseph G: Tumour necrosis factor (TNF)-α-308 gene polymorphism in Indian patients with Takayasu’s arteritis - a pilot study. Indian J Med Res 2013, 137(4):749-752.
• [16]Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate: Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008, 17(22):3532-3538.
• [17]Moos V, Rudwaleit M, Herzog V, Höhlig K, Sieper J, Müller B: Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. Arthritis Rheum 2000, 43(11):2417-2422.
• [18]Muñoz-Valle JF, Martin-Márquez BT: -308 tumor necrosis factor-alpha promoter polymorphism in patients with rheumatoid arthritis and osteoarthritis in the west of mexico: preliminary results(j). Rev Vaccimonitor (Vacunologíay Temasafines) 2002, 11(4):4.
• [19]Sezgin M, Barlas IO, Ankarali HC, Altintaş ZM, Türkmen E, Gökdoğan T, Sahin G, Erdal ME: Tumour necrosis factor alpha -308G/A gene polymorphism: lack of association with knee osteoarthritis in a Turkish population. Clin Exp Rheumatol 2008, 26(5):763-768.
• [20]Han L, Song JH, Yoon JH, Park YG, Lee SW, Choi YJ, Nam SW, Lee JY, Park WS: TNF-α and TNF-β Polymorphisms are Associated with Susceptibility to Osteoarthritis in a Korean Population. Korean J Pathol 2012, 46(1):30-37.
• [21]Muñoz-Valle JF, Oregón-Romero E, Rangel-Villalobos H, Martínez-Bonilla GE, Castañeda-Saucedo E, Salgado-Goytia L, Leyva-Vázquez MA, Illades-Aguiar B, Alarcón-Romero Ldel C, Espinoza-Rojo M, Parra-Rojas I: High expression of TNF alpha is associated with -308 and -238 TNF alpha polymorphisms in knee osteoarthritis. Clin Exp Med 2012. Epub ahead of print
• [22]Ji B, Shi J, Cheng X, Zhou J, Zhou Q, Cao C, Pang J: Association analysis of two candidate polymorphisms in the tumour necrosis factor-α gene with osteoarthritis in a Chinese population. Int Orthop 2013, 37(10):2061-2063.
• [23]Cheng XY, Cao CF, Ji B: Association of tumor necrosis factor- alpha -308 polymorphism with osteoarthritis in a Chinese population. Chin J Orthop Trauma 2013, 15(7):607-609.
• [24]Amin AR: Regulation of tumor necrosis factor-alpha and tumor necrosis factor converting enzyme in human osteoarthritis. Osteoarthritis Cartilage 1999, 7:392e4.
• [25]Goldring SR, Goldring MB: The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004, 427(Suppl):S27-S36.
• [26]Klooster AR, Bernier SM: Tumor necrosis factor alpha and epidermal growth factor act additively to inhibit matrix gene expression by chondrocyte. Arthritis Res Ther. 2005, 7(1):R127-R138. BioMed Central Full Text
• [27]Zhuang L, Ma W, Cai D, Zhong H, Sun Q: Associations between tumor necrosis factor-α polymorphisms and risk of psoriasis: a meta-analysis. PLoS One 2013, 8(12):e68827.
• [28]Miyamoto Y, Shi D, Nakajima M, Ozaki K, Sudo A, Kotani A, Uchida A, Tanaka T, Fukui N, Tsunoda T, Takahashi A, Nakamura Y, Jiang Q, Ikegawa S: Common variants in DVWA on chromosome 3p24.3 are associated with susceptibility to knee osteoarthritis. Nat Genet 2008, 40(8):994-998.
• [29]Meulenbelt I, Chapman K, Dieguez-Gonzalez R, Shi D, Tsezou A, Dai J, Malizos KN, Kloppenburg M, Carr A, Nakajima M, van der Breggen R, Lakenberg N, Gomez-Reino JJ, Jiang Q, Ikegawa S, Gonzalez A, Loughlin J, Slagboom EP: Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. Hum Mol Genet 2009, 18(8):1518-1523.
• [30]Nakajima M, Takahashi A, Kou I, Rodriguez-Fontenla C, Gomez-Reino JJ, Furuichi T, Dai J, Sudo A, Uchida A, Fukui N, Kubo M, Kamatani N, Tsunoda T, Malizos KN, Tsezou A, Gonzalez A, Nakamura Y, Ikegawa S: New sequence variants in HLA class II/III region associated with susceptibility to knee osteoarthritis identified by genome-wide association study. PLoS One 2010, 5(3):e9723.
• [31]Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, Blanco FJ, Carr A, Chapman K, Deloukas P, Doherty M, Esko T, Garcés Aletá CM, Gomez-Reino Carnota JJ, Helgadottir H, Hofman A, Jonsdottir I, Kerkhof HJ, Kloppenburg M, McCaskie A, Ntzani EE, Ollier WE, Oreiro N, Panoutsopoulou K, Ralston SH, Ramos YF, Riancho JA, Rivadeneira F, Slagboom PE, Styrkarsdottir U, Thorsteinsdottir U, et al.: Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies. Arthritis Rheumatol 2014, 66(4):940-949.
• [32]Güler-Yüksel M, Allaart CF, Watt I, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Schaardenburg D, van Krugten MV, Dijkmans BA, Huizinga TW, Lems WF, Kloppenburg M: Treatment with TNF-α inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage 2010, 18(10):1256-1262.
• [33]Chevalier X, Ravaud P, Maheu E, Baron G, Rialland A, Vergnaud P, Roux C, Maugars Y, Mulleman D, Lukas C, Wendling D, Lafforgue P, Loeuille D, Foltz V, Richette P, On behalf of the French section of osteoarthritis: Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2014. doi:10.1136/annrheumdis-2014-205348
• [34]Shi D, Zheng Q, Chen D, Zhu L, Qin A, Fan J, Liao J, Xu Z, Lin Z, Norman P, Xu J, Nakamura T, Dai K, Zheng M, Jiang Q: Association of single-nucleotide polymorphisms in HLA class II/III region with knee osteoarthritis. Osteoarthritis Cartilage 2010, 18(11):1454-1457.